IL295592A - Method of treating lower tract urothelial cancer - Google Patents
Method of treating lower tract urothelial cancerInfo
- Publication number
- IL295592A IL295592A IL295592A IL29559222A IL295592A IL 295592 A IL295592 A IL 295592A IL 295592 A IL295592 A IL 295592A IL 29559222 A IL29559222 A IL 29559222A IL 295592 A IL295592 A IL 295592A
- Authority
- IL
- Israel
- Prior art keywords
- antimetabolite
- individual
- bladder
- gemcitabine
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Materials For Medical Uses (AREA)
- Epoxy Compounds (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662333151P | 2016-05-06 | 2016-05-06 | |
| US201762443614P | 2017-01-06 | 2017-01-06 | |
| PCT/US2017/031445 WO2017193098A1 (en) | 2016-05-06 | 2017-05-05 | Method of treating lower tract urothelial cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL295592A true IL295592A (en) | 2022-10-01 |
Family
ID=60203435
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295592A IL295592A (en) | 2016-05-06 | 2017-05-05 | Method of treating lower tract urothelial cancer |
| IL262746A IL262746B (en) | 2016-05-06 | 2017-05-05 | A method for treating urothelial cancer in the lower system |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL262746A IL262746B (en) | 2016-05-06 | 2017-05-05 | A method for treating urothelial cancer in the lower system |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20190388338A1 (enExample) |
| EP (2) | EP3452053B1 (enExample) |
| JP (3) | JP7712055B2 (enExample) |
| KR (2) | KR20220123317A (enExample) |
| CN (2) | CN118453872A (enExample) |
| AU (1) | AU2017261371B2 (enExample) |
| CA (1) | CA3023274A1 (enExample) |
| ES (1) | ES2940227T3 (enExample) |
| FI (1) | FI3452053T3 (enExample) |
| HR (1) | HRP20221544T1 (enExample) |
| HU (1) | HUE060965T2 (enExample) |
| IL (2) | IL295592A (enExample) |
| LT (1) | LT3452053T (enExample) |
| MX (2) | MX389296B (enExample) |
| NZ (3) | NZ748252A (enExample) |
| PL (1) | PL3452053T3 (enExample) |
| PT (1) | PT3452053T (enExample) |
| RS (1) | RS64032B1 (enExample) |
| RU (2) | RU2022100624A (enExample) |
| SG (2) | SG11201809838VA (enExample) |
| SI (1) | SI3452053T1 (enExample) |
| SM (1) | SMT202300047T1 (enExample) |
| WO (1) | WO2017193098A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3370768T3 (da) | 2015-11-03 | 2022-03-21 | Janssen Biotech Inc | Antistoffer som specifikt binder pd-1 og anvendelser deraf |
| MX2019003683A (es) | 2016-10-11 | 2019-08-22 | Agenus Inc | Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos. |
| SG10201913998YA (en) * | 2017-07-25 | 2020-03-30 | Taris Biomedical Llc | Methods of treating tumor metastasis |
| MX2020004771A (es) | 2017-11-08 | 2020-10-19 | Taris Biomedical Llc | Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina. |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY30915A1 (es) * | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
| EA023156B1 (ru) | 2009-06-26 | 2016-04-29 | ТАРИС Биомедикал ЛЛК | Устройство для доставки лекарств |
| DK2512581T3 (da) | 2009-12-17 | 2021-03-29 | Taris Biomedical Llc | Implanterbar indretning med intravesikal tolerance |
| MX343671B (es) * | 2010-06-02 | 2016-11-16 | Abraxis Bioscience Llc * | Metodos de tratamiento de cancer de vejiga. |
| EP2600800B1 (en) | 2010-08-05 | 2020-09-30 | TARIS Biomedical LLC | Ureteral stent drug delivery device and kit |
| BR112013019410A2 (pt) | 2011-02-04 | 2019-09-24 | Taris Biomedical Inc | dispositivo implantável para liberação controlada de fármaco de solubilidade baixa |
| CN104470535A (zh) * | 2012-03-29 | 2015-03-25 | 阿尔托生物科学有限公司 | 用于治疗肿瘤的方法 |
| PL2890384T3 (pl) * | 2012-08-31 | 2022-02-14 | Taris Biomedical Llc | Układy podawania leku i sposoby leczenia raka pęcherza obejmujące oksaliplatynę |
| CA2882575C (en) | 2012-08-31 | 2020-05-26 | Dennis GIESING | Drug delivery systems and methods for treatment of prostate |
| EP2964310A1 (en) | 2013-03-05 | 2016-01-13 | TARIS Biomedical LLC | Drug delivery devices and methods for controlled drug release through device orifice |
| AU2014227914B2 (en) | 2013-03-15 | 2018-05-10 | Taris Biomedical Llc | Drug delivery devices and methods for drug delivery |
| PT2968880T (pt) | 2013-03-15 | 2025-07-07 | Taris Biomedical Llc | Dispositivos de aplicação de fármaco com componente permeável a fármaco |
| KR102503010B1 (ko) | 2013-08-19 | 2023-02-24 | 타리스 바이오메디컬 엘엘씨 | 다중 유닛 약물 전달 장치 및 방법 |
| CN119950539A (zh) | 2014-03-06 | 2025-05-09 | 塔里斯生物医药公司 | 用吉西他滨来治疗膀胱癌的药物递送系统和方法 |
| AU2015279674B2 (en) | 2014-06-26 | 2020-07-23 | Taris Biomedical Llc | Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems |
| JP7425534B2 (ja) | 2015-04-23 | 2024-01-31 | タリス バイオメディカル エルエルシー | 薬物透過性構成要素を有する薬物送達デバイス及び方法 |
-
2017
- 2017-05-05 NZ NZ748252A patent/NZ748252A/en unknown
- 2017-05-05 SI SI201731301T patent/SI3452053T1/sl unknown
- 2017-05-05 SM SM20230047T patent/SMT202300047T1/it unknown
- 2017-05-05 EP EP17793523.6A patent/EP3452053B1/en active Active
- 2017-05-05 HU HUE17793523A patent/HUE060965T2/hu unknown
- 2017-05-05 RS RS20230163A patent/RS64032B1/sr unknown
- 2017-05-05 WO PCT/US2017/031445 patent/WO2017193098A1/en not_active Ceased
- 2017-05-05 EP EP22212024.8A patent/EP4209221A1/en active Pending
- 2017-05-05 IL IL295592A patent/IL295592A/en unknown
- 2017-05-05 CN CN202410626384.1A patent/CN118453872A/zh active Pending
- 2017-05-05 SG SG11201809838VA patent/SG11201809838VA/en unknown
- 2017-05-05 HR HRP20221544TT patent/HRP20221544T1/hr unknown
- 2017-05-05 MX MX2018013432A patent/MX389296B/es unknown
- 2017-05-05 NZ NZ787786A patent/NZ787786A/en unknown
- 2017-05-05 RU RU2022100624A patent/RU2022100624A/ru unknown
- 2017-05-05 CA CA3023274A patent/CA3023274A1/en active Pending
- 2017-05-05 JP JP2018558199A patent/JP7712055B2/ja active Active
- 2017-05-05 CN CN201780040391.1A patent/CN109475571A/zh active Pending
- 2017-05-05 NZ NZ787824A patent/NZ787824A/en unknown
- 2017-05-05 RU RU2018142908A patent/RU2764747C2/ru active
- 2017-05-05 AU AU2017261371A patent/AU2017261371B2/en active Active
- 2017-05-05 FI FIEP17793523.6T patent/FI3452053T3/fi active
- 2017-05-05 KR KR1020227028547A patent/KR20220123317A/ko not_active Ceased
- 2017-05-05 KR KR1020187035297A patent/KR102435709B1/ko active Active
- 2017-05-05 LT LTEPPCT/US2017/031445T patent/LT3452053T/lt unknown
- 2017-05-05 PT PT177935236T patent/PT3452053T/pt unknown
- 2017-05-05 IL IL262746A patent/IL262746B/en unknown
- 2017-05-05 SG SG10201913416PA patent/SG10201913416PA/en unknown
- 2017-05-05 ES ES17793523T patent/ES2940227T3/es active Active
- 2017-05-05 US US16/099,179 patent/US20190388338A1/en active Pending
- 2017-05-05 PL PL17793523.6T patent/PL3452053T3/pl unknown
-
2018
- 2018-11-01 MX MX2021013461A patent/MX2021013461A/es unknown
-
2021
- 2021-10-21 JP JP2021172052A patent/JP2022009327A/ja not_active Withdrawn
-
2023
- 2023-12-07 JP JP2023206570A patent/JP2024028881A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chua et al. | Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis | |
| Zhao et al. | A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer | |
| JP2024028881A (ja) | 下部尿路上皮がんを処置する方法 | |
| Kaplan et al. | Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes | |
| Indolfi et al. | A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma | |
| US12059428B2 (en) | Methods of treating tumor metastasis | |
| CN113694009A (zh) | 用于使用微针的协同免疫化学治疗的透皮系统及其治疗方法 | |
| US11464734B2 (en) | Methods of treating overactive bladder using trospium | |
| US10792297B2 (en) | Methods of treatment and maintenance therapy for bladder cancer using gemcitabine | |
| HK40005970A (en) | Method of treating lower tract urothelial cancer | |
| HK40005970B (en) | Method of treating lower tract urothelial cancer | |
| KR20250000043A (ko) | 나노입자, 이의 제조 방법 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 | |
| BR122024005298A2 (pt) | Usos de antimetabólitos no tratamento de câncer urotelial do trato inferior, kits e dispositivo de liberação | |
| BR112018072551B1 (pt) | Kits para tratamento de câncer de bexiga músculo invasivo | |
| Qnouch | Silicone-based Implants for the treatment of the inner ear | |
| Tremosa et al. | NME Digest-July 2016 |